Literature DB >> 24725465

Patient-Controlled Remifentanil Analgesia as Alternative for Pethidine with Midazolam During Oocyte Retrieval in IVF/ICSI Procedures: A Randomized Controlled Trial.

Marit C Lier1,2, Wieteke M Douwenga2, Fatos Yilmaz2, Roel Schats1, Peter G Hompes1, Christa Boer2, Velja Mijatovic1.   

Abstract

BACKGROUND: Pethidine with midazolam-induced conscious sedation for pain relief during transvaginal oocyte retrieval for in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) procedures is associated with residual pain and oversedation. Patient-controlled analgesia (PCA) with remifentanil may serve as an alternative for pethidine. We investigated whether PCA remifentanil with diclofenac was associated with improved periprocedural pain relief than pethidine analgesia during IVF/ICSI procedures, with sedation scores, safety profiles, and patient satisfaction as secondary endpoints.
METHODS: Seventy-six women were randomized to receive pethidine (2 mg/kg i.m.) and midazolam (7.5 mg)-induced conscious sedation (n = 40) or PCA with remifentanil and diclofenac (50 mg; n = 36). The Numeric Rating Scale, McGill Pain Questionnaire (MPQ), Ramsey Sedation Scale, and a 5-day pain-and-discomfort diary were used to evaluate pain and sedation levels.
RESULTS: There were no differences in baseline characteristics and reproductive outcomes between both groups. Periprocedural pain scores were comparable for remifentanil and pethidine groups (4 [3 to 7] vs. 6 [4 to 8]; P = 0.13). Pain scores in the pethidine group were significantly lower at 30 minutes after the procedure (1 [0 to 3] vs. 2 [1 to 5]; P = 0.016), but at cost of higher sedation levels when compared to remifentanil (4 [2 to 4] vs. 2 [2 to 2]; P < 0.001). Patient satisfaction was higher, and MPQ scores were lower in the remifentanil group. There were no differences in safety profiles between both analgesics.
CONCLUSIONS: Patient-controlled analgesia with remifentanil showed a similar reduction in pain scores than pethidine with midazolam during oocyte retrieval, while pethidine induced the highest pain relief after the procedure. However, PCA remifentanil was associated with less sedation and a better patient satisfaction profile than pethidine.
© 2014 World Institute of Pain.

Entities:  

Keywords:  abdominal pain; analgesia; analgesics; conscious sedation; opioid; patient-controlled analgesia; remifentanil

Mesh:

Substances:

Year:  2014        PMID: 24725465     DOI: 10.1111/papr.12189

Source DB:  PubMed          Journal:  Pain Pract        ISSN: 1530-7085            Impact factor:   3.183


  5 in total

Review 1.  Nonsteroidal anti-inflammatory drugs for assisted reproductive technology.

Authors:  Atunga Nyachieo; Charalampos S Siristatidis; Dennis Vaidakis
Journal:  Cochrane Database Syst Rev       Date:  2019-10-19

2.  Randomized controlled trial of transcutaneous electrical nerve stimulation for pain relief during transvaginal oocyte retrieval using conscious sedation: study protocol for a randomized controlled trial.

Authors:  Queenie Ho Yan Wong; Man Wa Lui; Sofie Shuk Fei Yung; Jennifer Ka Yee Ko; Raymond Hang Wun Li; Ernest Hung Yu Ng
Journal:  Trials       Date:  2019-04-11       Impact factor: 2.279

Review 3.  Trends in research on pain relief during oocyte retrieval for IVF/ICSI: a systematic, methodological review.

Authors:  E T I A Buisman; H Grens; R Wang; S Bhattacharya; D D M Braat; A G Huppelschoten; J W van der Steeg
Journal:  Hum Reprod Open       Date:  2022-02-16

Review 4.  Pain relief for women undergoing oocyte retrieval for assisted reproduction.

Authors:  Irene Kwan; Rui Wang; Emily Pearce; Siladitya Bhattacharya
Journal:  Cochrane Database Syst Rev       Date:  2018-05-15

5.  Comparison of Two Different Sedation Protocols during Transvaginal Oocyte Retrieval: Effects on Propofol Consumption and IVF Outcome: A Prospective Cohort Study.

Authors:  Paraskevi Matsota; Tatiana Sidiropoulou; Tereza Vrantza; Maria Boutsikou; Elena Midvighi; Charalampos Siristatidis
Journal:  J Clin Med       Date:  2021-03-01       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.